Tucatinib/Tucatinib generics

Tucatinib/The original drug Tucatinib is currently on the market and sold in many overseas countries. It is an oral prescription drug for the treatment of breast cancer and colorectal cancer. It is understood that generic drugs of tucatinib are currently produced and sold overseas. Its pharmaceutical ingredients are basically the same as those of the original drug. There may be slight differences in production specifications, prices, etc. Common manufacturers of generic drugs include Laos No. 2 Factory, Bangladesh Ziska Pharmaceuticals, Bangladesh Everest Pharmaceuticals, etc.

Tucatinib is an oral drug that is a tyrosine kinase inhibitor of HER2, a protein that promotes the growth of cancer cells. HER2 is overexpressed in a variety of cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, tucatinib inhibited phosphorylation of HER2 and HER3, thereby inhibiting downstream MAPK and AKT signaling and cell growth (proliferation), and showed antitumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, tucatinib inhibited the growth of HER2-expressing tumors. The combination of tucatinib and the anti-HER2 antibody trastuzumab also showed enhanced antitumor activity in vitro and in vivo compared with either drug alone.

Currently, the original drug or generic version of tucatinib has not yet been sold in the domestic market. In the European market, the price of 150 mg 60 tablets per box may be as high as more than 70,000 RMB (the specific price may be affected by exchange rate fluctuations); while the 150 mg 30 tablets product produced by a Bangladesh pharmaceutical factory costs approximately more than 4,000 RMB (the price may fluctuate due to exchange rate changes). Compared with the original drug, this price is obviously much more affordable.